Browsing Clinical Studies by author "Banerjee, Susana"
Now showing items 1-2 of 2
-
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii, S; Gourley, C; Kumar, R; Geuna, E; Ern Ang, J; et al. (2017-07)Background The PARP inhibitor olaparib was recently granted Food and Drug Administration (FDA) accelerated approval in patients with advanced BRCA1/2 mutation ovarian cancer. However, antitumor responses are observed in ... -
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker.
Winfield, JM; Wakefield, JC; Dolling, D; Hall, M; Freeman, S; et al. (2019-11)Background Treatment of advanced epithelial ovarian cancer results in a relapse rate of 75%. Early markers of response would enable optimization of management and improved outcome in both primary and recurrent disease. ...